Niagen Bioscience, Inc. (NASDAQ: NAGE) announced that its senior leadership will participate in Canaccord Genuity’s 46th Annual Growth Conference, scheduled to take place in Boston from August 11 to 13, 2026. Chief Executive Officer Rob Fried and Chief Financial Officer Ozan Pamir will engage with investors during the event, highlighting the company’s position as a global authority on NAD+ (nicotinamide adenine dinucleotide) science and healthy aging. The participation aims to provide institutional investors with direct access to management insights regarding the company’s strategic direction and product portfolio, which includes the consumer supplement Tru Niagen and pharmaceutical-grade Niagen Plus.

Rob Fried is specifically scheduled to participate in a fireside chat on Tuesday, August 11, at 2:00 p.m. Eastern Time (11:00 a.m. Pacific Time). The session will be broadcast via webcast, and interested parties can register through the designated event portal. A replay of the fireside chat will be made available on the Niagen Bioscience Investor Relations website following the live event, ensuring broader accessibility for stakeholders unable to attend in person or view the stream in real time.

In addition to the public fireside chat, Mr. Fried and Mr. Pamir will hold one-on-one meetings with institutional investors throughout the conference duration. These private sessions are designed to facilitate deeper discussions on the company’s clinical advancements, patent portfolio protecting nicotinamide riboside (NR), and ongoing research into NB4168, a differentiated molecule developed under its wholly owned subsidiary, NAD Pharmaceuticals Corp. Investors seeking to arrange these meetings are instructed to contact their Canaccord Genuity representative or email the dedicated address provided by the company.

Niagen Bioscience continues to emphasize its focus on advancing healthspan through precision science. The company’s core product, Niagen, is described as the most efficient and well-researched NAD+ booster available, powering both oral supplements and intravenous/injectable products distributed through U.S. FDA-registered 503B outsourcing facilities. The firm maintains that NAD+ depletion is a key contributor to age-related health changes, positioning its solutions as critical interventions for vitality and longevity.

The company’s robust patent portfolio protects NR and other NAD+ precursors, reinforcing its competitive moat in the healthy aging sector. Niagen Bioscience collaborates with independent investigators from esteemed universities and research institutions globally to uncover the full potential of NAD+. For further information, investors and media can visit the company’s official website or contact Kendall Knysch, Senior Director of Media Relations & Partnerships, and Valter Pinto, Managing Director of KCSA Strategic Communications, who serves as the investor relations contact.

Niagen Bioscience, Inc. will announce its financial results for the second quarter ended June 30, 2026, on Tuesday, August 4, 2026. The company will release the results after the close of regular stock market trading hours. A conference call is scheduled for 4:30 p.m. ET to discuss the performance and provide a general business update.

Conference Call Details

Investors can access the live webcast or dial-in to listen to the discussion. The call will cover Niagen Bioscience’s second quarter financial results and business outlook.

The earnings press release and financial exhibits will be available in the Investor Relations section of Niagen Bioscience’s website at www.niagenbioscience.com .

About Niagen Bioscience

Niagen Bioscience, Inc. (NASDAQ: NAGE) focuses on the science of healthy aging and NAD+ (nicotinamide adenine dinucleotide). The company’s product portfolio includes Niagen®, a patented nicotinamide riboside, and Tru Niagen®, an oral supplement. Its subsidiary, NAD Pharmaceuticals Corp., is researching therapies for accelerated aging and rare genetic diseases.